



## X4 Pharmaceuticals Appoints William E. Aliski to Board of Directors

September 23, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 23, 2019-- [X4 Pharmaceuticals, Inc.](#) (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the appointment of William "Bill" E. Aliski to the Company's Board of Directors, effective September 18, 2019. Mr. Aliski has more than two decades of biopharmaceutical executive leadership experience at both public and private companies, with significant expertise in global rare disease commercialization, including a particular focus on commercial strategy, pricing, reimbursement and market access. Currently, Mr. Aliski serves as a member of the Boards of Directors of Ultragenyx Pharmaceutical Inc. and Applied Genetic Therapies Corporation.

"Bill's broad knowledge and demonstrated success across many areas of commercial activity will be invaluable to X4 as we continue to execute our Phase 3 clinical trial in WHIM syndrome and lay a strong foundation to build out our commercial infrastructure," said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. "We are pleased to welcome Bill to the Board, and look forward to leveraging his extensive experience and insights during this exciting and important period of growth for X4."

"I am excited to join this accomplished and committed team of industry leaders as we work together to bring novel therapies to patients with rare diseases who need more effective treatment options. I look forward to contributing my expertise as X4 pursues a potential first-in-class therapy for WHIM syndrome and prepares for commercialization," commented Mr. Aliski.

Since 2011, Mr. Aliski has served as an independent consultant to life sciences companies focused on orphan diseases, with particular focus on commercial strategy, market access, pricing, and reimbursement. Prior to 2011, he was Chief Commercial Officer for FoldRX Pharmaceuticals, an early stage company purchased by Pfizer in 2011, served as General Manager for Biomarin Europe, and held executive level positions at Transkaryotic Therapies (TKT)/Shire and Genzyme Corp.

In addition to Mr. Aliski's current Board appointments, he previously served on the Boards of Edimer Pharmaceuticals, a development stage company backed by Third Rock Ventures, and Scioderm Pharmaceuticals, Inc. (acquired in 2015 by Amicus Therapeutics). Mr. Aliski holds a Master of Public Administration from Harvard University and a Master of Social Planning from Boston College.

### About X4 Pharmaceuticals

X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company's oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4's most advanced product candidate, mavoxixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is also planning to commence clinical trials of mavoxixafor in Severe Congenital Neutropenia (SCN) and Waldenström's macroglobulinemia (WM) in 2019. X4 was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria. For more information, please visit [www.x4pharma.com](http://www.x4pharma.com).

### Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, statements regarding X4's business strategy, including its clinical development plans and preparations to commercialize its product candidates. These statements are subject to various risks and uncertainties, actual results could differ materially from those projected, and X4 cautions investors not to place undue reliance on the forward-looking statements in this press release. These risks and uncertainties include, without limitation, the risk that any one or more of X4's product candidates will not be successfully developed, approved or commercialized, the risk that X4's ongoing or planned clinical trials and studies may be delayed, and the risk that costs required to develop X4's product candidates or to expand its operations will be higher than anticipated. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, the risks and uncertainties described in the section entitled "Risk Factors" in X4's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as updated by X4's Current Report on Form 8-K filed with the SEC on April 11, 2019, and in other filings X4 makes with the SEC from time to time. X4 undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Source: X4 Pharmaceuticals, Inc.

**Investors:**

Stephanie Carrington  
Westwicke, an ICR company  
646-277-1282  
[Stephanie.Carrington@icrinc.com](mailto:Stephanie.Carrington@icrinc.com)

**Media:**

Darcie Robinson  
Westwicke, an ICR company  
203-919-7905  
[Darcie.robinson@icrinc.com](mailto:Darcie.robinson@icrinc.com)